Inhibition of nuclear accumulation of phosphorylated ERK by tropomyosin-1-mediated cytoskeletal reorganization

Journal of Cancer Molecules

Volumn 4, Issue 5, 2008, Pages 139-144

  Bharadwaj, Shantaram ^a   Vasanth, Girish ^b   Masuelli, Laura ^c   Thanawala, Ruchi ^a   Prasad, G L ^b,d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Triad Sciences   (United States)

Author keywords

Compartmentalization; Cytoskeleton; ERK; Ras; Subcellular; Tropomyosin 1

Indexed keywords

ALPHA TROPOMYOSIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL ACTIVATION; CELL COMPARTMENTALIZATION; CELL STRAIN 3T3; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSKELETON; ENZYME PHOSPHORYLATION; FIBROBLAST; IMMUNOBLOTTING; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE K RAS; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 63049128641     PISSN: 18160735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Fincham VJ, James M, Frame MC, Winder SJ. Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src. EMBO J 19: 2911-2923, 2000.
2. Leinweber BD, Leavis PC, Grabarek Z, Wang CL, Morgan KG. Extracellular regulated kinase (ERK) interaction with actin and the calponin homology (CH) domain of actin-binding proteins. Biochem J 344 (Pt 1): 117-123, 1999.
3. Mera A, Suga M, Nakayama Y, Ando M, Suda T, Yamaguchi N. Redistribution of ERK/MAP kinase to uropod-like structures in interleukin-3-induced cell shape changes. Immunol Lett 84: 117-124, 2002.
4. Christerson LB, Vanderbilt CA, Cobb MH. MEKK1 interacts with alpha-actinin and localizes to stress fibers and focal adhesions. Cell Motil Cytoskeleton 43: 186-198, 1999.
5. Woodring PJ, Litwack ED, O'Leary DD, Lucero GR, Wang JYJ, Hunter T. Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol 156: 879-892, 2002.
6. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183, 2001.
7. Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatiotemporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 64: 755-763, 2002.
8. Aplin AE, Juliano RL. Regulation of nucleocytoplasmic trafficking by cell adhesion receptors and the cytoskeleton. J Cell Biol 155: 187-191, 2001.
9. Aplin AE, Stewart SA, Assoian RK, Juliano RL. Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J Cell Biol 153: 273-282, 2001.
10. Smith ER, Smedberg JL, Rula ME, Xu X-X. Regulation of Ras-MAPK pathway mitogenic activity by restricting nuclear entry of activated MAPK in endoderm differentiation of embryonic carcinoma and stem cells. J Cell Biol 164: 689-699, 2004.
11. Gunning PW, Schevzov G, Kee AJ, Hardeman EC. Tropomyosin isoforms: divining rods for actin cytoskeleton function. Trends Cell Biol 15: 333-341, 2005.
12. Lin JJ, Warren KS, Wamboldt DD, Wang T, Lin JL. Tropomyosin isoforms in nonmuscle cells. Int Rev Cytology 170: 1-38, 1997.
13. Braverman RH, Cooper HL, Lee HS, Prasad GL. Anti-oncogenic effects of tropomyosin: isoform specificity and importance of protein coding sequences. Oncogene 13: 537-545, 1996.
14. Prasad GL, Fuldner RA, Cooper HL. Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. Proc Natl Acad Sci USA 90: 7039-7043, 1993.
15. Mahadev K, Raval G, Bharadwaj S, Willingham MC, Lange EM, Vonderhaar B, Salomon D, Prasad GL. Suppression of the transformed phenotype of breast cancer by tropomyosin-1. Exp Cell Res 279: 40-51, 2002.
16. Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T, Prasad GL. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 22: 6194-6203, 2003.
17. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genetics Dev 11: 41-47, 2001.
18. Prasad GL, William E, Balch CJ, Da AH. Regulation of the expression of tropomyosins and actin cytoskeleton by ras transformation. In: Method Enzymol Vol 407. Academic Press 2006: 410-422.
19. Masuelli L, Cutler ML. Increased expression of the Ras suppressor Rsu-1 enhances Erk-2 activation and inhibits Jun kinase activation. Mol Cell Biol 16: 5466-5476, 1996.
20. Shah V, Bharadwaj S, Kaibuchi K, Prasad GL. Cytoskeletal organization in tropomyosin-mediated reversion of rastransformation: evidence for Rho kinase pathway. Oncogene 20: 212-2121, 2001.
21. Bharadwaj S, Hitchcock-DeGregori S, Thorburn A, Prasad GL. N terminus is essential for tropomyosin functions: N-terminal modification disrupts stress fiber organization and abolishes antioncogenic effects of tropomyosin-1. J Biol Chem 279: 14039-14048, 2004.
22. Helfman DM, Pawlak G. Myosin light chain kinase and actomyosin contractility modulate activation of the ERK cascade downstream of oncogenic Ras. J Cell Biochem 95: 1069-1080, 2005.
23. Shah V, Braverman R, Prasad GL. Suppression of neoplastic transformation and regulation of cytoskeleton by tropomyosins. Somat Cell Mol Genet 24: 273-280, 1998.
24. Prasad GL, Fuldner RA, Braverman R, McDuffie E, Cooper HL. Expression, cytoskeletal utilization and dimer formation of tropomyosin derived from retroviral-mediated cDNA transfer. Metabolism of tropomyosin from transduced cDNA. Eur J Biochem 224: 1-10, 1994.
25. Ailenberg M, Silverman M. Cytochalasin D disruption of actin filaments in 3T3 cells produces an anti-apoptotic response by activating gelatinase A extracellularly and initiating intracellular survival signals. Biochim Biophys Acta - Mol Cell Res 1593: 249-258, 2003.
26. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6: 827-837, 2005.
27. Adachi M, Fukuda M, Nishida E. Two co-existing mechanisms for nuclear import of MAP kinase: passive diffusion of a monomer and active transport of a dimer. EMBO J 18: 5347-5358, 1999.
28. Adachi M, Fukuda M, Nishida E. Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J Cell Biol 148: 849-856, 2000.
29. Krueger J, Chou FL, Glading A, Schaefer E, Ginsberg MH. Phosphorylation of phosphoprotein enriched in astrocytes (PEA-15) regulates extracellular signal regulated kinasedependent transcription and cell proliferation. Mol Biol Cell 16: 3552-3561, 2005.
30. Glading A, Koziol JA, Krueger J, Ginsberg MH. PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res 67: 1536-1544, 2007.
31. Robinson MJ, Stippec SA, Goldsmith E, White MA, Cobb MH. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 8: 1141-1150, 1998.